GlassScriptPhysician profile
William Henry Baer
NPI 1184731333
$1,140.87
in general payments reported to CMS, 2019-2025
15 companies · $628 in 2025
The $628 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.56 · 2022: $15.20 · 2023: $38.06 · 2024: $448 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $516.63 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $106.54 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $91.12 | 2024-2025 | |
| Antares Pharma, INC. | $85.36 | 2024-2025 | Xyosted |
| Novo Nordisk INC | $63.82 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $45.02 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $38.85 | 2024 | |
| Eisai INC. | $38.79 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $31.50 | 2020-2025 | Breztri |
| International Rehabilitative Sciences, INC | $27.45 | 2025 | Rs-4i Plus With Intersperse |
| Heartflow, INC. | $22.15 | 2025 | |
| Ibsa Pharma INC. | $20.06 | 2025 | Flector, Licart, Tirosint |
| Lilly USA, LLC | $18.97 | 2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $18.24 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $16.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Baer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.